Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole

Clinical Schizophrenia and Related Psychoses

Volumn 5, Issue 2, 2011, Pages 75-79

  Ganguli, Rohan ^a,b   Brar, Jaspreet S ^b   Garbut, Ronald ^b   Chang, Chung Chou H ^b,c   Basu, Ranita ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Aripiprazole; Cardiovascular disease; Glucose; Medication switching; Metabolic syndrome; Obesity; Olanzapine; Schizophrenia; Weight loss

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; BODY WEIGHT; CAUCASIAN; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH HAZARD; HEART DISEASE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC PARAMETERS; OBESITY; OPEN STUDY; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CHANGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; METABOLIC SYNDROME X; MIDDLE AGED; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; WEIGHT LOSS;

EID: 80052148821     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.5.2.3     Document Type: Article

References (17)

1. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-389. (Pubitemid 34680462)
2. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 2003;60(7):681-690. (Pubitemid 36818630)
3. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-136. (Pubitemid 36513927)
4. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84(1):77-89. (Pubitemid 44255718)
5. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65 Suppl 18:47-56.
6. Casey DE, Carson WH, Saha AR, Leibeskind A, Ali MW, Jody D, et al.; Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166(4):391-399. (Pubitemid 36469941)
7. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008;69(7):1046-1056. (Pubitemid 352031586)
8. Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120(2):18-33.
9. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68(3):406-409. (Pubitemid 46506805)
10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261-276. (Pubitemid 18039085)
11. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005;162(8):1542-1543.
12. Mir A, Shivakumar K, Williamson RJ, McAllister V, O'Keane V, Aitchison KJ. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008;22(3):244-253. (Pubitemid 351847447)
13. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003;35(3):237-241. (Pubitemid 38591665)
14. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioural therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66(2):205-212. (Pubitemid 40314327)
15. Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res 2007;96(1-3):198-205. (Pubitemid 47494625)
16. Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 2007;91(1-3):169-177.
17. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189(2):259-266. (Pubitemid 44691547)